Pet Pharm Biotech Co., Ltd. (7762.TWO)
Taipei Exchange · TWD · Healthcare · Drug Manufacturers - General
NT$51.00 (+0.20%) as of
Key statistics
- Market cap
- 2.96B
- P/E (TTM)
- 98.08
- EPS (TTM)
- 0.52
- Dividend yield
- 0.49%
- 52-week range
- 44.00 – 77.83
- Beta
- 0.72
- Revenue (TTM)
- 265.54M
- Profit margin
- 11.31%
- Volume
- 28.44k
About Pet Pharm Biotech Co., Ltd.
Pet Pharm Biotech Co., Ltd. manufactures and sells pharmaceutical products. The company also engages in the research, development, and production of nuclear medicine drugs. Its products include FDG fluodeoxyglucose, naolixi, and sodium fluoride injections; and radioactive sodium iodide capsules. The company was founded in 2011 and is based in New Taipei City, Taiwan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- New Taipei City, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.